



fw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/672,059 Confirmation No.: 4726
Applicant : Linda ARTERBURN et al.
Filed : September 29, 2003
Title : PROPHYLACTIC DHA THERAPY FOR PATIENTS WITH
SUBCLINICAL INFLAMMATION INCLUDING DIABETIC AND
PREDIABETIC PATIENTS
TC/Art Unit : 1614
Examiner: : Unassigned

Docket No. : 62611.000234
Customer No. : 21967

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants are submitting herewith copies of the references listed on the attached Form PTO-SB/08A (modified) for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

Additionally, several of the attached documents were cited by the European Patent Office in the International Search Report dated April 26, 2004 of the corresponding application and relevance as asserted by the Searching Authority is indicated on the enclosed copy of the Search Report.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(e), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action, and within three months of the date of the corresponding Search Report.. Therefore, it is respectfully submitted that no fee is

required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.


Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: May 19, 2004

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

By:



Jeffrey T. Perez
Registration No. 52,110

JTP/sdw

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/672,059
Filing Date	September 29, 2003
First Named Inventor	Linda ARTERBURN et al.
Art Unit	1614
Examiner Name	Unassigned

Sheet	1	of	4	Attorney Docket Number	62611.000234
-------	---	----	---	------------------------	--------------

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 5508310	04-16-1996	Rhodes	
	2.	US 5720304	02-24-1998	Omura	
	3.	US 20020055538	05-09-2002	Serhan et al.	

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
	4.	EP	0675103 A3	10-04-1995	Horrobin et al.			

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	5.	FREEMAN et al., "C-Reaction Protein Is an Independent Predictor of Risk for the Development of Diabetes in the West of Scotland Coronary Prevention Study," Diabetes, Vol. 51, May 2002, pp. 1596-1600		
	6.	Diabetes In Control.com, "C-Reactive Protein Predicts Diabetes Risk in Middle-Age Men," Item #5, 2 pages		
	7.	American Family Physician, November 15, 1999, Tips from other Journals, "Low- vs. High-Dose Aspirin After Carotid Endarterectomy," 2 pages		
	8.	SERHAN et al., "Anti-Microinflammatory Lipid Signals Generated From Dietary N-3 Fatty Acids Via Cyclooxygenase-2 and Transcellular Processing: A Novel Mechanism For NSAID And N-3 PUFA Therapeutic Actions," Journal of Physiology and Pharmacology, 2000, 51, 4, pp. 643-654		

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number		10/672,059	
				Filing Date		September 29, 2003	
				First Named Inventor		Linda ARTERBURN et al.	
				Art Unit		1614	
				Examiner Name		Unassigned	
Sheet	2	of	4	Attorney Docket Number		62611.000234	
NON-PATENT LITERATURE DOCUMENTS							
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION				
			YES	NO			
	9.	SERHAN et al., "Novel Functional Sets of Lipid-derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2-Nonsteroidal Antiinflammatory Drugs and Transcellular Processing," JEM online, 192 (8):1197, printed 7/7/03, { http://www.jem.org/cgi/content/full/192/8/1197 }, pp. 1-14					
	10.	BLANCO et al., "Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes," J. Rheumatol, 1999 Jun, 26 (6): 1366-73, Pub Med Abstract printed 7/7/03					
	11.	SERHAN et al., "Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals," J. Exp. Med. 2002 Oct.;196(8): 1025-37, Pub Med Abstract printed 7/7/03					
	12.	SVANEBOG et al., "The acute and short-time effect of supplementation with the combination of n-3 fatty acids and acetylsalicylic acid on platelet function and plasma lipids," Thromb Res. 2002 Feb15;1054(4):311-6, Pub Med Abstract printed 7/7/03					
	13.	PATRIGNANI et al., "COX-2 is is not involved in thromboxane biosynthesis by activated human platelets," J. Physiol Pharmacol. 1999 Dec;50(4):661-7, Pub Med Abstract printed 7/7/03					
	14.	ANIL et al., "Effect of n-3 fatty acids on VLDL production by hepatocytes is mediated through prostaglandins," Biochem Mol. Biol. Int. 1997 Dec.;43(5):1071-80, Pub Med Abstract printed 7/7/03					
	15.	HINZ et al., "Salicylate metabolites inhibit cyclooxygenase-2-dependent prostaglandin E(2) synthesis in murine macrophages," Biochem. Biophys. Res. Commun. 2000 Jul. 21;274(1):197-202, Pub Med Abstract printed 7/7/03					
	16.	HAWKEY, "COX-1 and COX-2 inhibitors," Best Pract. Res. Clin. Gastroenterol. 2001 Oct; 15(5):801-20, Pub Med Abstract printed 7/7/03					
	17.	PRADHAN et al., "Can serum markers predict the development of type 2 diabetes mellitus?," MD Digests, printed 8/21/02, 1 page, { http://www.healthstream.com/mddigestsmain.cfm?MDDigestID=1190 }					
	18.	TEMELKOVA-KURKTSCHIEV et al., "Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance," Diabetologia 2002 Jan.;45(1):151, Pub Med Abstract printed 8/22/02					
EXAMINER SIGNATURE				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute for form 1449A/PTO				Application Number	10/672,059
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Filing Date	September 29, 2003
				First Named Inventor	Linda ARTERBURN et al.
				Art Unit	1614
				Examiner Name	Unassigned
Sheet	3	of	4	Attorney Docket Number	62611.000234
NON-PATENT LITERATURE DOCUMENTS					
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION		
	19.	VISSER et al., "Elevated C-Reaction Protein Levels in Overweight and Obese Adults," JAMA, Vol. 282, No. 22, December 8, 1999, Abstract printed 8/21/02 { http://jama.ama-assn.org/issues/v282n22/abs/joc91041.html }	YES	NO	
	20.	BERMUDEZ et al., "C-Reactive protein (CRP), statins, and the primary prevention of atherosclerotic cardiovascular disease," Medscape from WebMD, { http://www.medscape.com/viewarticle/433236 }, printed 9/18/03, 2 pages			
	21.	HART et al., "Aspirin dosage and thromboxane synthesis in patients with vascular disease," Pharmacotherapy 23(5):579-584, 2003, Medscape Abstract, { http://www.medscape.com/viewarticle/455732 }, 9 pages			
	22.	MADSEN et al., "C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease," The American Journal of Cardiology, Vol. 88, Issue 10, 15 November 2001, pages 1139-1142, Science @ Direct Abstract, 1 page			
	23.	JEYARAJAH et al., Docosahexaenoic acid, a component of fish oil, inhibits nitric oxide production in vitro," J. Surg. Res. 1999 May 15;83(2):147-50, Pub Med Abstract printed 9/17/03, 1 page			
	24.	MIYAZAKI et al., "Dietary docosahexaenoic acid ameliorates, but rapeseed oil and safflower oil accelerate renal injury in stroke-prone spontaneously hypertensive rats as compared with soybean oil, which is associated with expression for renal transforming growth factor-beta, fibronectin and renin," Biochim. Biophys. Acta. 2000 Jan. 3;1483(1):101-10, Pub Med Abstract printed 9/17/03, 1 page			
	25.	YANO et al., "Docosahexaenoic acid and vitamin E can reduce human monocytic U937 cell apoptosis induced by tumor necrosis factor," J. Nutr. 2000 May; 130(5):1095-101, Pub Med Abstract printed 9/17/03, 1 page			
	26.	TEMELKOVA-KURKTSCHIEV et al., "Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes," Metabolism 2002 Jun; 51(6):743-9, Pub Med Abstract printed 8/22/02, 2 pages			
	27.	GALLOWAY et al., "Insulin-induced hypoglycemia induces a rise in C-reactive protein," Diabetes Care, 2000 Jun;23(6):861-2, Pub Med Abstract printed 8/22/02, 3 pages			
	28.	HANKEY et al., "Antiplatelet drugs," eMJA Abstract, MJA 2003; 178(11): 568-574, 13 pages			
EXAMINER SIGNATURE				DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Substitute for form 1449A/PTO				Application Number 10/672,059	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Filing Date September 29, 2003	
				First Named Inventor Linda ARTERBURN et al.	
				Art Unit 1614	
				Examiner Name Unassigned	
Sheet	4	of	4	Attorney Docket Number 62611.000234	
NON-PATENT LITERATURE DOCUMENTS					
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION		
	29.	OFFERMANN, "Antiplatelet Drugs," Molecular Pharmacology, 3 pages	YES	NO	
	30.	SARGENT et al., "Recent developments in the essential fatty acid nutrition of fish," Aquaculture 177 (1999) 191-199			
	31.	JAMES et al., "Dietary polyunsaturated fatty acids and inflammatory mediator production," Am. J. Clin. Nutr., 2000 Jan;71(1 Suppl):343S-8S, Pub Med Abstract printed 9/17/03, 1 page			
	32.	WATANABE et al., "Dietary docosahexaenoic acid but not eicosapentaenoic acid suppresses lipopolysaccharide-induced interleukin-1 beta mRNA induction in mouse spleen leukocytes," Prostaglandins Leukot. Essent. Fatty Acids., 2000 Mar.;62(3):147-52, Pub Med Abstract printed 9/17/03, 1 page			
	33.	ARTS et al., "Essential fatty acids" in aquatic ecosystems: a crucial link between diet human health and evolution," Can. J. Fish. Aquat. Sci. 58: 122-137 (2001)			
	34.	Clinical Insights Fax Program, Issue No. 29 (October 2, 2000), National Diabetes Education Initiative For Healthcare Professionals, printed 8/21/02, {http://www.ndei.org/content/ndeipubs/clinical_insights/fax100200.asp}			
	35.	CRP, Inflammation, and Subclinical Atherosclerosis," Medscape from WebMD, printed 9/18/03, {http://www.medscape.com/viewarticle/433236_2}, 1 page			
	36.	International Search Report dated April 26, 2004 for Application No. PCT/US03/30484			
	37.	GRIEGER, "Diabetes and cardiovascular disease," printed from {http://www.heartinfo.org/search/print.asp?id}, printed 8/21/02, 3 pages			
EXAMINER SIGNATURE				DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					